Blue Cross NC policies, page 7

Search Blue Cross NC's public medical, payment and drug policies by CPT or HCPCS code, keyword or policy number, with links to the payer's own documents. Links open the payer's own document; check its current version before relying on it.

1,022 public policies Substrate tracks for Blue Cross NC, by title.

Blue Cross NC policies
PolicyDetailsCodesSource
Facility Emergency Department E&M ServicesEffective Dec 15, 2025 · Commercial10Original policy ↗
Facility Emergency Department E&M ServicesEffective May 1, 2024 · Commercial10Original policy ↗
Facility Emergency Department E&M ServicesEffective Dec 15, 2025 · Medicaid10Original policy ↗
Facility Emergency Department E&M ServicesEffective Jan 1, 2026 · Medicaid10Original policy ↗
Facility Standards (PDF)Commercial—Original policy ↗
Facility Standards for Urgent Care Providers (PDF)Commercial—Original policy ↗
Facility Take-Home DME and Medical SuppliesG-06081 · Effective May 22, 2024 · Medicaid—Original policy ↗
Familial Adenomatous Polyposis and MUTYH-Associated Polyposis AHSM2024AHSM2024 · Commercial6Original policy ↗
Fecal Analysis in the Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing AHS - G2060G2060 · Commercial31Original policy ↗
Fecal Calprotectin Testing AHS – G2061G2061 · Commercial2Original policy ↗
FEP Dental® Provider Summary Book (PDF)Commercial5Original policy ↗
Ferritin AHS – G2011G2011 · Commercial1Original policy ↗
Fibromyalgia Testing AHS - M2177M2177 · Commercial3Original policy ↗
Flow Cytometry AHS - F2019F2019 · Commercial14Original policy ↗
Flow Cytometry AHS – F2019F2019 · Commercial14Original policy ↗
Focal Treatments for Prostate CancerCommercial7Original policy ↗
Folate Testing AHS - G2154G2154 · Commercial3Original policy ↗
Folate Testing AHS – G2154G2154 · Commercial2Original policy ↗
For Number of Available Providers (PDF)Commercial—Original policy ↗
For Visits to Primary Care Physicians (PDF)Commercial—Original policy ↗
For Visits to Specialists (PDF)Commercial—Original policy ↗
Foresee Home AMD Monitoring3Original policy ↗
Functional Capacity Assessment and Work HardeningCommercial4Original policy ↗
Gamma-glutamyl Transferase Testing in Adults AHS-G2173AHS-G2173 · Commercial1Original policy ↗
Gastric Electrical StimulationCommercial19Original policy ↗
Gastroesophageal Reflux Disease, Transendoscopic TherapiesCommercial15Original policy ↗
Gene Expression Based Assays for Cancers of Unknown Primary AHS - M2065M2065 · Commercial4Original policy ↗
Gene Expression Profiling and Protein Biomarkers for Prostate Cancer AHS - M2166AHS - M2166 · Commercial31Original policy ↗
Gene Expression Profiling for Uveal Melanoma AHS- M2071AHS-M2071 · Commercial1Original policy ↗
General Genetic Testing, Germline Disorders AHS - M2145M2145 · Commercial109Original policy ↗
General Genetic Testing, Germline Disorders AHS – M2145M2145 · Commercial77Original policy ↗
General Genetic Testing, Somatic Disorders AHS - M2146AHS-M2146 · Commercial92Original policy ↗
General Genetic Testing, Somatic Disorders AHS-M2146AHS-M2146 · Commercial54Original policy ↗
General Inflammation Testing AHS - G2155G2155 · Commercial4Original policy ↗
General Inflammation Testing AHS – G2155G2155 · Commercial3Original policy ↗
Genetic and Molecular TestingEffective Feb 1, 2026 · Commercial4Original policy ↗
Genetic and Molecular TestingCommercial1Original policy ↗
Genetic and Molecular TestingCommercial4Original policy ↗
Genetic Cancer Susceptibility Panels Using Next Generation Sequencing AHS - M2066M2066 · Commercial11Original policy ↗
Genetic Expression Profiling and Genetic Testing for Familial Cutaneous Malignant Melanoma AHS – M2037M2037 · Commercial4Original policy ↗
Genetic Markers for Assessing Risk of Cardiovascular Disease AHS - M2180M2180 · Commercial14Original policy ↗
Genetic Testing and Genetic Expression Profiling in Patients with Uveal Melanoma AHS - M2071M2071 · Commercial6Original policy ↗
Genetic Testing for 5 Fluorouracil Use in Cancer Patients AHS-M2067AHS-M2067 · Commercial3Original policy ↗
Genetic Testing for Acute Myeloid Leukemia AHS-M2062AHS-M2062 · Commercial15Original policy ↗
Genetic Testing for Adolescent Idiopathic Scoliosis AHS – G2036G2036 · Commercial1Original policy ↗
Genetic Testing for Alpha Thalassemia AHS – M2131M2131 · Commercial4Original policy ↗
Genetic Testing for Alpha- and Beta- Thalassemia AHS - M2131M2131 · Commercial12Original policy ↗
Genetic Testing for Breast, Ovarian, Pancreatic and Prostate Cancers (BRCA) AHS - M2003M2003 · Commercial20Original policy ↗
Genetic Testing for Breast, Ovarian, Pancreatic and Prostate Cancers (BRCA) AHS - M2003M2003 · Commercial19Original policy ↗
Genetic Testing for Cardiac Ion Channelopathies AHS – 2025Commercial14Original policy ↗

Back to Blue Cross NC · Blue Cross NC prior authorization CPT list

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.